全文获取类型
收费全文 | 29310篇 |
免费 | 2657篇 |
国内免费 | 100篇 |
专业分类
耳鼻咽喉 | 193篇 |
儿科学 | 942篇 |
妇产科学 | 615篇 |
基础医学 | 3921篇 |
口腔科学 | 656篇 |
临床医学 | 3950篇 |
内科学 | 5305篇 |
皮肤病学 | 279篇 |
神经病学 | 3092篇 |
特种医学 | 832篇 |
外科学 | 3540篇 |
综合类 | 564篇 |
一般理论 | 38篇 |
预防医学 | 3559篇 |
眼科学 | 544篇 |
药学 | 1932篇 |
1篇 | |
中国医学 | 45篇 |
肿瘤学 | 2059篇 |
出版年
2023年 | 127篇 |
2022年 | 202篇 |
2021年 | 396篇 |
2020年 | 274篇 |
2019年 | 449篇 |
2018年 | 488篇 |
2017年 | 459篇 |
2016年 | 445篇 |
2015年 | 495篇 |
2014年 | 793篇 |
2013年 | 1175篇 |
2012年 | 1681篇 |
2011年 | 1930篇 |
2010年 | 1023篇 |
2009年 | 908篇 |
2008年 | 1644篇 |
2007年 | 1749篇 |
2006年 | 1708篇 |
2005年 | 1775篇 |
2004年 | 1724篇 |
2003年 | 1659篇 |
2002年 | 1577篇 |
2001年 | 645篇 |
2000年 | 677篇 |
1999年 | 602篇 |
1998年 | 389篇 |
1997年 | 359篇 |
1996年 | 317篇 |
1995年 | 252篇 |
1994年 | 243篇 |
1993年 | 260篇 |
1992年 | 414篇 |
1991年 | 373篇 |
1990年 | 394篇 |
1989年 | 304篇 |
1988年 | 359篇 |
1987年 | 292篇 |
1986年 | 274篇 |
1985年 | 269篇 |
1984年 | 244篇 |
1983年 | 209篇 |
1982年 | 197篇 |
1981年 | 181篇 |
1980年 | 175篇 |
1979年 | 208篇 |
1978年 | 151篇 |
1977年 | 136篇 |
1976年 | 119篇 |
1974年 | 135篇 |
1973年 | 126篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Tselios Konstantinos Yap Kristy Su-Ying Pakchotanon Rattapol Polachek Ari Su Jiandong Urowitz Murray B. Gladman Dafna D. 《Clinical rheumatology》2019,38(1):269-269
Clinical Rheumatology - Prof. Ari Polachek on of the author of the published version of this article missed to add his second affiliation which is the Department of Rheumatology, Tel Aviv Sourasky... 相似文献
6.
Sweeka Alexander Gurjeet Dulku Sharbell Hashoul Donna B Taylor 《Journal of Medical Imaging and Radiation Oncology》2019,63(4):473-478
Contrast‐enhanced spectral mammography (CESM) has a number of uses including the work‐up of inconclusive findings on mammography, assessment of breast symptoms, cancer staging, evaluation of response to neoadjuvant chemotherapy and recently as an alternative to magnetic resonance imaging (MRI) in high‐risk screening. CESM can be swiftly incorporated into the workflow of busy breast clinics. We share our experiences with CESM at a large breast assessment centre in Western Australia. 相似文献
7.
8.
Darren R. Feldman MD Yasser Ged MBBS Chung-Han Lee PhD Andrea Knezevic MS Ana M. Molina MD Ying-Bei Chen PhD Joshua Chaim DO Devyn T. Coskey MS Samuel Murray MS Satish K. Tickoo MD Victor E. Reuter MD Sujata Patil PhD Han Xiao MD Jahan Aghalar MD Arlyn J. Apollo MD Maria I. Carlo MD Robert J. Motzer MD Martin H. Voss MD 《Cancer》2020,126(24):5247-5255
9.
Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. 总被引:8,自引:0,他引:8
Michael W Kattan Martin S Karpeh Madhu Mazumdar Murray F Brennan 《Journal of clinical oncology》2003,21(19):3647-3650
PURPOSE: Few published studies have addressed individual patient risk after R0 resection for gastric cancer. We developed and internally validated a nomogram that combines these factors to predict the probability of 5-year gastric cancer-specific survival on the basis of 1,039 patients treated at a single institution. METHODS: Nomogram predictor variables included age, sex, primary site (distal one-third, middle one-third, gastroesophageal junction, and proximal one-third), Lauren histotype (diffuse, intestinal, mixed), number of positive lymph nodes resected, number of negative lymph nodes resected, and depth of invasion. Death as a result of gastric cancer was the predicted end point. The concordance index was used as an accuracy measure, with bootstrapping to correct for optimistic bias. Calibration plots were constructed. RESULTS: Gastric cancer-specific survival at 5 years was 50%. A nomogram was constructed on the basis of a Cox regression model. The bootstrap-corrected concordance index was 0.80. When compared with the predictive ability of American Joint Committee on Cancer stage, the nomogram discrimination was superior (P <.001). Nomogram calibration appeared to be excellent. CONCLUSION: A nomogram was developed to predict 5-year disease-specific survival after R0 resection for gastric cancer. This tool should be useful for patient counseling, follow-up scheduling, and clinical trial eligibility determination. 相似文献
10.